Currently serving as an Oncologist and Director of Cellular Therapy Service at Massachusetts General Hospital and Instructor of Medicine at Harvard Medical School. His research experience includes pre-clinical development and correlative studies relevant to T-cell immunotherapy as well as therapies utilizing marrow infiltrating lymphocytes and chimeric switch receptors. Dr. Frigault’s current research focuses on the translational aspects of cellular therapies with the goal of developing the next generation of cellular therapies utilizing multi-cistronic lentiviral vectors, CRISPR gene editing and clinical correlatives.
Attending Physician in the Division of Hematologic Oncology, Leukemia Service at Memorial Sloan Kettering Cancer Center. He is currently the lead investigator of MSKCC's Chimeric Antigen Receptor T-cell (CAR-T) therapy in ALL and CLL. Dr. Park has also written numerous peer-reviewed articles, book chapters, and editorials, and his research has been recognized and funded by the AACR, ASCO, Leukemia and Lymphoma Society, Geoffrey Beene Research Foundation, and NCCN.